Should You Keep an Eye on These Eye Treatment Biotechs?
Leo is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Investors might want to keep their eyes on the eye care industry, as the battle for eye treatments heats up across the biotech sector. Two eye diseases -- wet AMD (age-related macular degeneration) and DME (diabetic macular edema) -- are at the center of a big battle that includes Roche (NASDAQOTH: RHHBY), Novartis (NYSE: NVS), Regeneron Pharmaceuticals (NASDAQ: REGN), and Ampio Pharmaceuticals (NYSEMKT: AMPE).
Wet (neovascular) AMD causes abnormal blood vessels to grow and leak fluid into the macula, and is the leading cause of blindness in the elderly. DME, on the other hand, is an eye disease that is caused by diabetes, and causes severe vision loss and blindness. The market for both is expected to grow substantially over the next few years, as the world’s population ages and cases of diabetes rise.
A traditional treatment and a cheaper alternative
When patients are diagnosed with AMD, Lucentis (ranibizumab) is considered the traditional treatment, which is usually delivered via an injection once per month. However, the injections cost $2,000 each, which has led some patients to reduce injections to once every three months after the first four months of treatment.
Within the United States, Lucentis is marketed by Roche’s subsidiary Genentech, but Novartis holds exclusive rights for the rest of the world. The U.S. FDA has approved the use of Lucentis for the treatment of both AMD and DME.
Lucentis has two major drawbacks, however.
The first drawback is a fatality warning stating that over a three year period, there was a death rate of 6.4% in patients treated with 0.5 mg doses, and a 4.4% rate in those treated with 0.3 mg doses. Roche and Novartis note that the fatality rate included the death of patients with advanced diabetic complications, but that the potential relationship between the deaths and the intravitreal use of VEGF inhibitors (proteins which Lucentis uses to spur the growth of new blood vessels) could not be excluded.
Lucentis’ second weakness is its unfavorable comparison to Avastin (bevacizumab), a multi-use angiogenesis inhibitor approved by the FDA for the treatment of colon, lung, and renal cancer, as well as malignant brain tumors. Clinical studies over the past three years have shown that Avastin, also manufactured by Genentech/Roche, is equally effective in treating AMD and DME, for a fraction of the cost. A single dose of Avastin only costs $100.
This has led many critics to claim that there was no reason for specially formulated AMD and DME drugs like Lucentis to even exist on the market. However, that hasn’t stopped other competitors from entering the market with their own treatments.
Eylea has its eyes on the prize
Regeneron’s Eylea, which was approved by the FDA in November 2011 for the treatment of AMD and CRVO (central retinal vein occlusion), is Lucentis’ biggest competitor. Eylea has not been approved for the treatment of DME, although the company has reported positive results from its Phase 3 trials. Eylea was developed through a collaboration with Bayer.
Regeneron is hoping that Eylea, which costs roughly the same as Lucentis per injection, will be more appealing since it is not required to be labeled with a fatality warning like Lucentis. However, Eylea faces the same threat from the lower-priced and equally effective Avastin. Yet, that hasn’t stopped Regeneron and Bayer from submitting new drug applications to the FDA and worldwide regulatory agencies for its approval as a DME treatment.
Since Regeneron only has two other approved drugs on the market, Arcalyst (rilonacept) and Zaltrap (Aflibercept), Eylea is considered the key catalyst for the company to continue growing. Therefore, when Regeneron reported a slowdown in Eylea sales during the second quarter, shares plunged 6%.
Sales of Eylea rose 70% year-on-year to $330 million, but it was a dramatic drop from the 153% growth it reported in the previous quarter. Eylea sales accounted for 72% of Regeneron’s top line, which rose 50.3% year-on-year to $457.6 million. Regeneron’s earnings rose from $0.70 to $0.79 per share.
Ampio keeps the needles away from the eyes
Eylea’s strong sales also encouraged another company, the much smaller Ampio Pharmaceuticals, to abruptly declare that its low-dose steroid Optina for DME could be approved soon by the FDA. Ampio’s statement, in which it claimed that positive Phase III results could soon lead to FDA approval, has been harshly criticized by a number of analysts. Optina is an orally administered drug that the company considers a safer alternative to injections of Lucentis and Eylea.
The main criticism is that Ampio’s “Phase III” trials should actually be classified as Phase II trials, due to the efficacy and safety data gathered from the trial. In addition, Ampio’s planned clinical study for Ampio is intended for a 12-week period on 450 DME patients. To date, the FDA has never approved a DME treatment based on the results of a 12-week trial.
Lucentis was only approved as a DME treatment after two Phase III studies showed significant improvement in patients. Regeneron’s Phase III trials for using Eylea as a DME treatment are measuring vision improvement over a two-year period. Therefore, Ampio’s statement that a 12-week trial would eventually lead to FDA approval is a very weak claim.
A Foolish final thought
It’s a fact that the number of AMD and DME cases will increase annually as a result of an aging world population and rising diabetes rates. However, it’s unknown if any of these new treatments can offer any real advantages over Avastin. The slowdown in Eylea sales last quarter indicates that many patients are switching over to the cheaper alternative instead. Yet, that discouraging data hasn’t stopped companies like Regeneron and Ampio from betting heavily that these expensive treatments could become a reliable source of future revenue growth.
In closing, investors should carefully watch the fluctuation in demand between the angiogenesis inhibitors (Lucentis and Eylea) and Avastin to see if these eye treatments are truly worth all the Wall Street hype that has been showered upon them.
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.
Leo Sun has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Is this post wrong? Click here. Think you can do better? Join us and write your own!